Weight-based dosing: Which impact on efficacy and safety of therapy?

Digestive and Liver Disease

Volumn 36, Issue SUPPL. 3, 2004, Pages

  Almasio, Piero Luigi ^a  

^a UNIVERSITY OF PALERMO   (Italy)

Author keywords

Chronic hepatitis C; Pegylated interferon; Weight based dosing

Indexed keywords

ALANINE AMINOTRANSFERASE; ALPHA2A INTERFERON; ALPHA2B INTERFERON; PEGINTERFERON; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; RIBAVIRIN; VIRUS RNA; ANTIVIRUS AGENT; INTERFERON; MACROGOL DERIVATIVE; PEGINTERFERON ALFA-2A; PEGINTERFERON ALFA-2B;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; BODY WEIGHT; CLINICAL TRIAL; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG SAFETY; HEPATITIS C; HUMAN; LOGISTIC REGRESSION ANALYSIS; MONOTHERAPY; NEUTROPENIA; PREDICTION; SIDE EFFECT; TREATMENT OUTCOME; VIROLOGY; BODY MASS; DOSE RESPONSE; DRUG COMBINATION; REVIEW;

ANTIVIRAL AGENTS; BODY MASS INDEX; BODY WEIGHT; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG THERAPY, COMBINATION; HEPATITIS C, CHRONIC; HUMANS; INTERFERON ALFA-2A; INTERFERON ALFA-2B; INTERFERONS; POLYETHYLENE GLYCOLS; RIBAVIRIN; TREATMENT OUTCOME;

EID: 18444405857     PISSN: 15908658     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1590-8658(04)80005-7     Document Type: Article

References (12)

1. McHutchison J.G. Gordon S.C. Schiff E.R. Shiffman M.L. Lee W.M. Rustgi V.K. et al. Interferon alpha-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. International Hepatitis InterventionalTherapy Group N Engl J Med 339 1998 1493-1499
2. Poynard T. Marcellin P. Lee S.S. Niederau C. Minuk G.S. Idea G. et al. Randomised trial of interferon alpha-2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha-2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group Lancet 352 1998 1426-1432
3. Manns M.P. McHutchison J.G. Gordon S.C. Rustgi V.K. Shiffman M. Reindollar R. et al. Peginterferon alpha-2b in combination with ribavirin compared with interferon alpha-2b plus ribavirin for initial treatment of chronic hepatitis C:results of a randomised trial Lancet 358 2001 958-965
4. Fried M.W. Shiffman M.L. Reddy K. Smith C. Marino G. Goncales F. et al. Peginterferon alpha-2a plus ribavirin for chronic hepatitis C virus infection N Engl J Med 347 2002 975-982
5. National Institutes of Health Consensus Development Conference. National Institutes of Health Consensus Development Conference Statement.Management of hepatitis C: 2002. June 10-12, 2002 Hepatology 36 Suppl 2 2002 S3-S20
6. Zeuzem S. Feinman S.V. Rasenack J. Heathcote E.J. Lai M.Y. Gane E. et al. Peginterferon alpha-2a in patients with chronic hepatitis C N Engl J Med 343 2000 1666-1672
7. Lee S.S. Heathcote E.J. Reddy K.R. Zeuzem S. Fried M.W. Wright T.L. et al. Prognostic factors and early predictability of sustained response with peginterferon alpha-2a (40kD) J Hepatol 37 2002 500-506
8. Lindsay K.L. Trepo C. Heintges T. Shiffman M.L. Gordon S.C. Hoefs J.C. et al. The Hepatitis Interventional Therapy Group. A randomized, double-blind trial comparing pegylated interferon alpha-2b to interferon alpha-2b as initial treatment for chronic hepatitis C Hepatology 34 2001 395-403
9. Schering-Plough Corporation. Data on file.
10. FDA analysis of the Fried and Hadziyannis study. FDA briefing document. http://www.fda.gov/ohrms/dockets/ac/02/briefing/ 3909B1_02_FDA%20briefing%20%package%20.doc.
11. Hadziyannis S.J. Sette H. Jr Morgan T.R. Balan V. Diago M. Marcellin P. et al. Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: A randomized study of treatment duration and ribavirin dose Ann Intern Med 140 2004 346-355
12. Zeuzem S. Hultcrantz R. Bourliere M. Goeser T. Marcellin P. Sanchez-Tapias J. et al. Peginterferon alpha-2b plus ribavirin for treatment of chronic hepatitis C in previously untreated patients infected with HCV genotypes 2 or 3 J Hepatol 40 2004 993-999